Plain-English translation of NCT03954171 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers want to understand why some ovarian cancers stop responding to platinum-based chemotherapy, a standard first-line treatment. This study will collect blood samples, tumor tissue, and fluid samples from patients receiving this treatment to identify biological markers that predict who might develop resistance. By learning more about these resistance patterns, doctors hope to better predict treatment outcomes and improve care for future patients.
Platinum chemotherapy works well for many ovarian cancer patients, but some cancers eventually stop responding to the medication. Understanding what causes this resistance could help doctors identify at-risk patients earlier and develop better treatment strategies.
You likely qualify if…
You likely don't qualify if…
You will receive your standard platinum-based chemotherapy and surgery as planned with your medical team. During your regular hospital visits over 5 years, researchers will collect additional blood samples, tumor tissue samples, and fluid samples that would normally be taken anyway for your care. You will also have information about your treatment and health collected into a research database. There are no additional procedures or extra visits required beyond your standard cancer care.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
France